Club ITnews
 Username:
 
 Password:
   
accesso automatico
Registrati    Password
ITnews homepage
 
ITnews-letter
  
 Iscrivi  Rimuovi
Rubriche
Servizi stampa
Risorse e servizi

New Study Shows That Pegasys Regimen Provides Higher Cure Rates for Hepatitis C Patients

Notizia pubblicata in rete il 01/11/2008 12:00, tempo medio di lettura previsto 3 minuti e 50 secondi


BASEL, Switzerland, November 1 /PRNewswire/ -- A new, independently-conducted study being presented at AASLD shows that PEGASYS(R) (peginterferon alfa-2a (40KD)) regimens result in higher cure rates for hepatitis C patients compared to regimens with another pegylated interferon.(1)
Comparing Today's Standard Treatment Regimens: The Milan Safety Tolerability Study
Prof. Colombo, Head of the 1st Division of Gastroenterology and A.M. Migliavacca Center for Liver Disease at the University of Milan, and colleagues will present the results of a study which found significantly higher cure rates in patients treated with Pegasys/ribavirin compared to those treated with peginterferon alfa-2b (PegIntron(TM)))/ribavirin (66% vs. 54%, p=0.02). The difference was even more pronounced in patients with the most difficult-to-treat forms of the virus, those infected with genotypes 1 or 4 (48% vs. 32%, p=0.02). The two regimens showed a similar safety and tolerability profile, with similar rates of serious adverse events (2% in both arms) and drop outs for side effects (7% vs. 6%).(1)
"Our study combines the rigor of a randomised, controlled trial with the general applicability of a 'real-world' study, since it included all patients at our clinic who initiated hepatitis C treatment and met basic eligibility criteria," said Prof Colombo. "The results from this study prove that treatment success rates in the real world can be comparable to those achieved in clinical trials, and the study also demonstrates that Pegasys regimens enable significantly more patients to achieve a cure."
The Milan Safety Tolerability (MIST) Study randomly assigned 431 patients to receive Pegasys or peginterferon alfa-2b, both in combination with ribavirin. In the Pegasys group, the daily ribavirin dose for genotype 1 and 4 patients was 1,000-1,200 mg based on weight, while patients with genotype 2 or 3 received a fixed dose of ribavirin (800 mg). In the peginterferon alfa-2b group, ribavirin doses ranged from 800 mg to 1,400 mg based on a patient's weight in all genotypes.
Since the study used different ribavirin dosing in the treatment arms, it cannot provide a direct, head-to-head comparison between Pegasys and peginterferon alfa-2b, but instead offers comparisons between the specific combination regimens.
Notes for Editors
About Chronic Hepatitis C
Hepatitis C (HCV), the most common chronic blood-borne infection, is transmitted primarily through blood or blood products. HCV chronically affects 180 million people worldwide, which makes it over four times more prevalent than HIV. It is a leading cause of cirrhosis, liver cancer and liver failure, despite the fact that many patients can be cured.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at http://www.roche.com.
References:
1) Rumi M, Aghemo A, Prati G, et al. Randomized study comparing peginterferon-alfa-2a plus ribavirin and peginterferon-alfa2b plu s ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability Study. Abstract presented at the American Association for the Study of Liver Disease; 31 October 2008; San Francisco, California, USA.
Contact: Mike Nelson, Roche, +41-79-572-5165
Copyright: 2010 PR Newswire Europe. All rights to PR Newswire Content are owned by PR Newswire Association LLC and/or its Affiliates or used under l icence from their licensors. Any copying or other use of PR Newswire Content including without limitation by caching, framing, linking or otherwise is expressly forbidden without the prior written consent of PR Newswire Europe Limited or an appropriate Affiliate.
Servizi Notizie correlate

  Invia notizia via e-mail
  Visualizza Panorama
  Notizie correlate
  Notizie stesso ambito

  Crescita del mobile banking per le persone che non hanno accesso ai servizi bancari, mentre CGAP e DFID annunciano una nuova partnership
  President Obama Donates US$125,000 of Nobel Prize Money to American Indian College Fund
  CoreObjects Receives Project Management Institute's 'Excellence Award' for Diabetes Contribution

 ITnews E-Card
Ufficio stampa: PR Newswire Association LLC

Riferimenti: Consulta altre Notizie dello stesso Ufficio Stampa (VPO)

Ultime notizie
12/03/2010 13:30 Asian Markets Overview of March 12, 2010
12/03/2010 10:30 ABN Newswire Stocks to Watch: March 12, 2010
12/03/2010 02:30 Crescita del mobile banking per le persone che non hanno accesso ai servizi bancari, mentre CGAP e DFID annunciano una nuova partnership
12/03/2010 01:10 President Obama Donates US$125,000 of Nobel Prize Money to American Indian College Fund
12/03/2010 01:00 CoreObjects Receives Project Management Institute's 'Excellence Award' for Diabetes Contribution
12/03/2010 00:07 Finavera Renewables Awarded Four Electricity Purchase Agreements in BC Hydro Clean Power Call
12/03/2010 00:01 MS Society Comments on Social Care Report
11/03/2010 23:47 Banco Cruzeiro do Sul Announced in Sao Paulo Today (3/11) That it Will Sponsor the Racer Bruno Senna and the HRT Team During the 2010 Formula 1 Season
11/03/2010 22:28 Examiner's Report in Lehman Brothers Bankruptcy Available Online at lehmanreport.jenner.com
11/03/2010 22:02 School of Sustainability Graduate Students Launch Sustainability Journal
11/03/2010 21:51 U.S. Department of State Announces Winners of Global Online Video Contest: 'Change Your Climate, Change Our World'
11/03/2010 21:30 Regionali: Campania, accolti dal Tar i ricorsi di due liste a sostegno di De Luca
11/03/2010 20:55 Giustizia: Anm, accuse premier a toghe non ci intimidiscono
11/03/2010 20:39 Superenalotto: nessun '6' e '5+' e il jackpot sale a 46,7 mln euro
11/03/2010 20:35 Terremoto: Bindi, garantire voto a cittadini zone colpite


NICE ITnews. Copyright © 1999-2010 NICE Srl. Riproduzione riservata.
Il portale ITnews è realizzato a Roma in Via Nomentana 186 da NICE S.r.l. - P.IVA 05124321000
Registrazione al Tribunale di Roma n.209 del 27/05/2004 - ISSN 1723-7351.
Editore e proprietario: NICE S.r.l., Direttore responsabile: Nicola Bruno
 ADVERTISING
 NOTE LEGALI
 CONTATTI
 PRIVACY
Associato
Unione Stampa
Periodica Italiana